Erbitux Hearing May Feature FDA Reviewer Communication Policies

The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications